Fibromyalgia Syndrome and Vitiligo: A Novel Association.

Objectives This study aims to assess the relationship between fibromyalgia syndrome (FMS) and vitiligo in Iraqi patients and evaluate the predictors of this relationship, if present. Patients and methods The case-control study included 100 Iraqi patients (46 males, 54 females; mean age 30.4±14 years; range 15 to 65 years) with vitiligo and 200 age- and sex-matched healthy controls (74 males, 126 females; mean age 30.3±9.4 years; range 15 to 62 years). Baseline characteristics of patients and controls were recorded. The 2012 Canadian Guidelines criteria were used for the diagnosis of FMS and applied to all patients and controls. Results Prevalence of FMS in vitiligo patients and controls was 12% and 7%, respectively (p=0.15, odds ratio=1.8, 95% confidence interval=0.8-4.08). FMS symptoms in vitiligo patients were fatigue (46%), diffuse body pain (34%), sleep disturbance (33%), cognitive dysfunction (30%), and mood disorders (23%), while visceral involvements were central nervous system (52%), skin (35%), gastrointestinal tract (32%), cardiovascular system- respiratory system (16%), genitourinary tract (8%), and ear nose throat (7%). Of vitiligo patients, FMS was significantly more common among females (22.2%) compared to none among males (0%) (p<0.05). Prevalence of FMS was restricted to female sex only and a significantly higher prevalence rate of FMS was found among female vitiligo patients (22.2%) compared to controls (9.5%). Receiving phototherapy significantly increased the risk of having FMS by 5 times compared to female patients not receiving phototherapy. Use of any steroid reduced the risk of having FMS by 2.5 times (inverse of odds ratio=0.4) among females patients (p>0/05). No significant association was found between FMS in vitiligo patients and age, disease duration, type of vitiligo, use of any immunosuppressant and body mass index (p>0.05). Conclusion Fibromyalgia syndrome was more prevalent in vitiligo patients compared to controls, which was clinically important but statistically not significant. There was a significant association between FMS in vitiligo patients and female sex, severe form of vitiligo, and receiving phototherapy. This may suggest that early diagnosis of FMS in vitiligo patients may help in early treatment and subsequently improve patients' quality of life.

[1]  I. Altunay,et al.  Cutaneous findings in fibromyalgia syndrome and their effect on quality of life , 2016 .

[2]  G. Mohammed,et al.  Highlights in pathogenesis of vitiligo. , 2015, World journal of clinical cases.

[3]  A. Sousa,et al.  Psychological Morbidity in Vitiligo-A Case Control Study , 2015 .

[4]  Yvonne C. Lee,et al.  Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia , 2015, Arthritis Research & Therapy.

[5]  S. Somaiah,et al.  Quality-of-life and psychosocial impact of vitiligo in Indian patients , 2015 .

[6]  F. Gorial,et al.  Fibromyalgia Syndrome AmongIraqi Patients with Systemic Lupus Erythematosus : A Case Control Study , 2015 .

[7]  N. Allı,et al.  Fibromyalgia syndrome in chronic urticaria patients , 2014 .

[8]  K. Kingo,et al.  Quality of life and emotional state in vitiligo in an Estonian sample: comparison with psoriasis and healthy controls. , 2013, Acta dermato-venereologica.

[9]  H. Nakagawa,et al.  Guidelines for the diagnosis and treatment of vitiligo in Japan , 2013, The Journal of dermatology.

[10]  M. Mansuri,et al.  Vitiligo: interplay between oxidative stress and immune system , 2013, Experimental dermatology.

[11]  M. Magrey,et al.  High Frequency of Fibromyalgia in Patients with Psoriatic Arthritis: A Pilot Study , 2013, Arthritis.

[12]  Susan Abbey,et al.  COPYRIGHT PULSUS GROUP INC. – DO NOT COPY , 2013 .

[13]  M. Melikoğlu,et al.  The prevalence of fibromyalgia in patients with Behçet’s disease and its relation with disease activity , 2013, Rheumatology International.

[14]  Filippo Castoldi,et al.  Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment , 2012, Pain research and treatment.

[15]  M. Karkucak,et al.  Sociodemographic characteristics, clinical signs and quality of life in patients with fibromyalgia. , 2012, The Eurasian journal of medicine.

[16]  W. Qidwai,et al.  Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. , 2012, Oman medical journal.

[17]  Z. Kutlubay,et al.  Vitiligo as an Autoimmune Disease , 2012 .

[18]  K. Sharquie Common Hypopigmented Skin Disorders in Baghdad Teaching hospital , 2011 .

[19]  I. Failde,et al.  Fibromyalgia and psychiatric comorbidity: their effect on the quality of life patients. , 2010, Actas espanolas de psiquiatria.

[20]  O. Vasseljen,et al.  Association between physical exercise, body mass index, and risk of fibromyalgia: Longitudinal data from the Norwegian Nord‐Trøndelag Health Study , 2010, Arthritis care & research.

[21]  H. Erdem,et al.  Comorbidity of fibromyalgia and cervical myofascial pain syndrome , 2010, Clinical Rheumatology.

[22]  A. Osman,et al.  The psychological impact of vitiligo in adult Sudanese patients. , 2009, African journal of psychiatry.

[23]  B. Fantino,et al.  Rheumatoid Arthritis and Fibromyalgia: A Frequent Unrelated Association Complicating Disease Management , 2009, The Journal of Rheumatology.

[24]  M. Petri,et al.  Fibromyalgia, Systemic Lupus Erythematosus (SLE), and Evaluation of SLE Activity , 2008, The Journal of Rheumatology.

[25]  M J Watts,et al.  Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.

[26]  P. Sarzi-Puttini,et al.  Fibromyalgia and autoimmune diseases: the pain behind autoimmunity. , 2008, The Israel Medical Association journal : IMAJ.

[27]  S. Guldıken,et al.  Frequency of rheumatic diseases in patients with autoimmune thyroid disease , 2007, Rheumatology International.

[28]  R. Singh,et al.  Psychiatric Morbidity in Psoriasis and Vitiligo: A Comparative Study , 2001, The Journal of dermatology.